Completed
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
NCT05576779
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, COVID-19, +16 more
- Locations
-
- Novartis Investigative Site East Hanover, New Jersey, United States